Drug-labels.com

IPG-Letrozole: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
2.5 mg
Active ingredient:
ATC code:

Patient Medication Information: uses, side effects, how to take - IPG-Letrozole

What IPG-LETROZOLE is used for:

  • The adjuvant treatment of postmenopausal women with hormone receptor-positive invasive early breast cancer;
  • The extended adjuvant treatment of hormone receptor positive invasive early breast cancer in postmenopausal women who have received approximately 5 years of prior standard adjuvant tamoxifen therapy.
  • The first-line therapy in postmenopausal women with advanced breast cancer; and
  • The hormonal treatment of advanced metastatic breast cancer after relapse or disease progression in women with natural or artificially-induced postmenopausal endocrine status, who have previously been treated with antiestrogens.

What does IPG-LETROZOLE do;

Estrogen is a normally occurring female sex hormone that stimulates normal breast tissue and the growth of some types of breast cancer. IPG-LETROZOLE is an aromatase inhibitor which acts by binding to aromatase, a substance needed to make estrogen. As a result, the production of estrogen and the growth of breast cancer are reduced.

What is adjuvant therapy:

Adjuvant therapy in breast cancer refers to treatment following breast surgery (the primary or initial treatment) in order to reduce the risk of recurrence. The purpose of adjuvant therapy with IPG-LETROZOLE is to treat hormone receptor-positive early breast cancer, after surgery, in postmenopausal women to reduce the risk of recurrence.

WARNINGS AND PRECAUTIONS

What is extended adjuvant therapy:

The purpose of extended adjuvant therapy with MAR-LETROZOLE is to treat hormone receptor-positive early breast cancer in postmenopausal women who have received approximately 5 years of prior standard adjuvant tamoxifen therapy in order to prevent recurrence. Treating breast cancer with IPG-LETROZOLE beyond the standard 5 years of hormone therapy is called "extended adjuvant therapy".

When it should not be used:

IPG-LETROZOLE should not be used in children and adolescents under 18 years of age.

IPG-LETROZOLE should not be used in hormone-receptor negative diseases.

Do not take IPG-LETROZOLE if you:

  • have ever had an unusual or allergic reaction to letrozole or any other ingredient in MAR-LETROZOLE;
  • still have menstrual periods;
  • are pregnant or breast-feeding, as IPG-LETROZOLE may harm your baby.

What the medicinal ingredient is:

Letrozole

What the nonmedicinal ingredients are:

IPG-Letrozole also contains the following non-medicinal ingredients needed to make the tablets: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, pregelatinized starch, colloidal silicon dioxide, magnesium stearate and opadry yellow (contains: hypromellose, titanium dioxide, ferric oxide (yellow), polyethylene glycol 8000 and talc.)

What dosage forms it comes in:

IPG-Letrozole (letrozole) 2.5 mg tablets

IPG-Letrozole is supplied as yellow, round, film-coated tablets with debossed one side with “N” and other side “L”.

IPG-Letrozole is supplied in HDBE bottles of 30 and 100 tablets and blister packs containing 3x10 tablets.

Serious Warnings and Precautions

IPG-Letrozole should be used under the supervision of a doctor experienced in the use of anti-cancer drugs.

IPG-Letrozole reduces blood estrogen levels which may cause a reduction in bone mineral density and a potential increase in bone loss (osteoporosis) and/or bone fractures.

IMPORTANT: PLEASE READ

The use of aromatase inhibitors, including IPG-LETROZOLE IPG-LETROZOLE, may increase the risk of cardiovascular events compared to tamoxifen, such as heart attacks and stroke. Women at risk of heart disease should be carefully monitored by their doctor.

You should not use IPG-LETROZOLE if you may become pregnant or are pregnant. There is a potential risk of harm to you and the fetus. There are reports of spontaneous abortions and abnormalities in babies born to mothers who took IPG-LETROZOLE during pregnancy. If you have the potential to become pregnant (this includes women who are perimenopausal or who recently became postmenopausal), you should discuss with your doctor about the need for effective contraception. Use effective birth control during treatment and for at least 20 days after stopping IPG-LETROZOLE. Ask your doctor about options of for effective birth control.

INTERACTIONS WITH THIS MEDICATION

You should not use IPG-LETROZOLE if you are breastfeeding. There is a potential risk of harm to breastfeed babies.

IPG-LETROZOLE may reduce fertility in males.

If there is exposure to IPG-LETROZOLE during pregnancy, you should contact your doctor immediately to discuss the potential of harm to your fetus and potential risk for loss of the pregnancy.

PROPER USE OF THIS MEDICATION

IPG-LETROZOLE should not be used in children and adolescents under 18 years of age.

Before you take IPG-LETROZOLE:

Tell your doctor if you:

  • have a serious kidney or serious liver disease;
  • are taking hormone replacement therapy;
  • are taking other medication to treat your cancer;
  • have a personal or family history of osteoporosis or have ever been diagnosed with low bone density or have a recent history of fractures (in order for your doctor to assess your bone health on a regular basis);
  • have a personal or family history of high blood cholesterol or lipid levels. IPG-LETROZOLE may increase lipid levels.
  • have or have had cardiovascular or heart disease including any of the following: heart attack, stroke or uncontrolled blood pressure. IPG-LETROZOLE may increase the risk of cardiovascular or heart diseases;

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

  • have an intolerance to milk sugar (lactose);
  • have pain in bones, or joints or muscles.

    Driving a vehicle or using machinery:

    IPG-LETROZOLE tablets are unlikely to affect your ability to drive a car or to use machinery. However, some patients may occasionally feel tired, dizzy, sleepy or experience visual disorders. If this happens, you should not drive or operate any tools or machinery until you feel normal again.

    Please tell your doctor or pharmacist if you are taking or have recently taken any other prescription or over-the-counter medicines, vitamins or natural health products during your treatment with IPG-LETROZOLE. This includes in particular:

    • Tamoxifen.
    • Other anti-estrogens or estrogen-containing therapies.

These substances may diminish the action of IPG-LETROZOLE.

Usual dose:

The usual dosage is one tablet of IPG-LETROZOLE to be taken once daily. The tablet should be swallowed whole with a small glass of water. You can take IPG-LETROZOLE with or without food. It is best to take IPG-LETROZOLE at about the same time every day.

Overdose:

If overdosage is known or suspected, contact your doctor or the nearest poison control centre for advice immediately. Show the pack of tablets. Medical treatment may be necessary.

Missed Dose:

If you forget to take a dose of IPG-LETROZOLE, don’t worry, take the missed dose as soon as you remember. However, if it is almost time for the next dose (e.g. within 2 or 3 hours), skip the missed dose and go back to your regular dosage schedule. Do not take a double dose to make up for the one that you missed.

As with all medicines, patients taking IPG-LETROZOLE may experience side effects. Most side effects that have

IMPORTANT: PLEASE READ

been observed were mild to moderate and will generally disappear after a few days to a few weeks of treatment. Check with your doctor if the unwanted effects do not go away during treatment or become bothersome.

Some side effects, such as hot flushes, hair loss or vaginal bleeding may be due to the lack of estrogen in your body.

Very common side effects (they affect more than 10 in every 100 patients)

  • increased level of cholesterol (hypercholesterolemia)
  • hot flushes
  • increased sweating
  • night sweats
  • fatigue (including weakness and malaise (generally feeling unwell)
  • pain in bones and joints (arthralgia).

Common side effects (they affect between 1 to 10 in every 100 patients)

  • headache
  • rash
  • dizziness
  • gastrointestinal disorders (such as, nausea, vomiting, indigestion, constipation, diarrhea)
  • increase in or loss of appetite
  • increased blood sugar (hyperglycaemia)
  • urinary incontinence
  • pain in muscles
  • bone loss (osteoporosis)
  • bone fractures
  • depression
  • weight increase
  • anxiety
  • insomnia
  • hair loss
  • vaginal bleeding
  • dry skin
  • raised blood pressure (hypertension)
  • abdominal pain
  • back pain
  • fall
  • palpitations (rapid heart rate)
  • joint stiffness (arthritis)
  • chest pain

Uncommon side effects (they affect between 1 to 10 in every 1000 patients)

  • nervous disorders (such as nervousness, irritability, drowsiness)
  • pain or burning sensation in the hands or wrists (carpal tunnel syndrome)

    • reduced sense of touch (dysaesthesia)
    • eye irritation
    • itchy rash (urticaria), rapid swelling of face, lips, tongue, throat (angioedema)
    • severe allergic reaction (anaphylactic reaction)
    • vaginal disorders (such as discharge or dryness)
    • breast pain
    • fever
    • thirst, taste disorder, dry mouth
    • dryness of mucous membranes
    • weight decrease
    • urinary tract infection, increased frequency of urination
    • cough
    • abnormal liver function test results (blood test disorders)
    • Increased bilirubin level (dark coloured urine)
    • Jaundice (yellowish eyes and/or skin).

Side effects with frequency not known

  • trigger finger, a condition in which your finger or thumb catches in a bent position.

If any of these affects you severely, tell your doctor.

If you notice any other side effects not listed in this leaflet, please tell your doctor or pharmacist.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM
Symptom / effectTalk with your doctor or pharmacistStop taking drug and call your doctor or pharmacist
Only if severeIn all cases
Common

-Pain in muscles, bones and joints;

-Joint stiffness;

-Persistent sad mood (i.e. depression)

√

√

√
Uncommon
-Tightness or feeling of heaviness in the chest or pain radiating from your chest to your arms or shoulders, neck, teeth or jaw, abdomen or back (signs of angina pectoris or heart attack);√

IMPORTANT: PLEASE READ

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM
Symptom / effectTalk with your doctor or pharmacistStop taking drug and call your doctor or pharmacist
Only if severeIn all cases
-Numbness or weakness in arm or leg or any part of the body, loss of coordination, vision changes, sudden headache, nausea, loss of coordination, difficulty in speaking or breathing (sign of brain disease e.g. stroke)√

-Swelling and redness along a vein which is extremely tender and possibly painful when touched (signs of inflammation of a vein due to a blood clot, e.g. thrombophlebitis),

-Difficulty breathing, chest pain, fainting rapid heart rate, bluish skin discoloration (signs of blood clot formation in the lung such as pulmonary embolism),

-Swelling of arms, hands, feet, ankles or other parts of the body (signs of oedema),

-Swelling mainly of the face and throat (signs of allergic reaction)

-Severe fever, chills or mouth ulcers due to infections (signs of low level of white blood cells).

-Blurred vision (sign of cataract).

-Yellow skin and eyes, nausea, loss of appetite, dark coloured urine (signs of hepatitis)

-Rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (signs of skin disorder)

√

√

√

√

√

√

√

√

This is not a complete list of side effects. For any unexpected effects while taking IPG-LETROZOLE, contact your doctor or pharmacist.

HOW TO STORE IT

Store your tablets in a dry place at room temperature 15 to 30 °C. Avoid places where the temperature may rise above 30°C. Protect from moisture.

Keep this medicine out of the reach and sight of children and pets

Expiry date: Do not take IPG-LETROZOLE after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month. Remember to take any unused medication back to your pharmacist.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

  • Visiting the Web page on Adverse Reaction Reporting (http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php) for information on how to report online, by mail or by fax; or
  • Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice

If you want more information about IPG-LETROZOLE:

  • Talk to your healthcare professional
  • Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (https://health-products.canada.ca/dpd-bdpp/index-eng.jsp); the manufacturer’s website (www. https://www.marcanpharma.com ), or by calling 1-855-627-2261. This leaflet was prepared by Last Revised

2 Gurdwara Road, Suite #112, Ottawa, ON, K2E 1A2

Last Revised: March 24, 2020

IMPORTANT: PLEASE READ

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02370794

Revision date stated in the text: March 24, 2020

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for IPG-Letrozole

Rx or OTC
Prescription (Rx)?
DIN 02370794
Schedule(s) PRESCRIPTION
Active ingredient(s) Letrozole 2.5 MG
Dosage form(s) Tablet
Route(s) of administration Oral
Drug class (WHO ATC)
  1. L Antineoplastic and immunomodulating agents
    1. L02 Endocrine therapy antineoplastic and immunomodulating agents
      1. L02B Hormone antagonists and related agents
        1. L02BG Aromatase inhibitors
          1. L02BG04 Letrozole
Company MARCAN PHARMACEUTICALS INC
Current status Approved
Current status date June 24, 2016

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.